Fremont, Kalif., 4. März 2024 (ots/PRNewswire) – Das zweite Jahr in Folge erhält Lam die jährliche Auszeichnung für sein Engagement für geschäftliche Integrität durch solide Ethik, Compliance und Governance. Lam Research Corp. (NASDAQ: LRCX) gab heute bekannt, dass das Unternehmen die Auszeichnung World“s Most Ethical Companies® 2024 von Ethisphere erhalten hat, einem weltweit führenden Unternehmen […] Lam Research wird von Ethisphere als eines der ethischsten Unternehmen der Welt 2024 ausgezeichnet®

CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering… 

Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo